Skip to main content
JBIO logo

JBIO · Jade Biosciences, Inc.

Track JBIO — free
$21.40 +0.38 (+1.81%)
Market Cap
$1.34B
Shares
63.60M

JBIO metrics

50 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$21.02
Market cap
$1.34B

Price action

19 metrics
Price change (1W)
-3.8%
Price change (30D)
+9.8%
Price change (3M)
+18.4%
Price change (6M)
+51.1%
Price change (YTD)
+36.2%
Price change (1Y)
+166.1%
Trailing year
Price change (5Y)
52-week high
$26.85
52-week low
$6.95
Change from 52-week high
-21.7%
Change from 52-week low
+202.4%
Annualized volatility
73.6%
Beta
1.4
RSI (14D)
46.3
Price vs SMA 50
-2.0%
Price vs SMA 200
+17.6%
Avg volume (3M)
1.08M
Relative volume
0.5
Average dollar volume
$21.49M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
63.60M

Valuation

12 metrics
P / E (TTM)
2.5
Trailing earnings · reciprocal yield 40.2%
PEG ratio
EV / revenue
EV / EBITDA
EV / EBIT
P / sales
P / book
3.0
reciprocal yield 32.9%
FCF yield
TTM · current market cap
Buyback yield
P / FCF
P / operating cash flow
Earnings yield
-11.5%

Historical valuation

8 metrics
P / E historical average (3Y)
P / E historical average (5Y)
EV / revenue historical average (3Y)
EV / revenue historical average (5Y)
EV / EBIT historical average (3Y)
EV / EBIT historical average (5Y)
EV / EBITDA historical average (3Y)
EV / EBITDA historical average (5Y)

Dividends & buybacks

7 metrics
Dividend yield
Trailing 12 months
Payout ratio
Shareholder yield
Dividend / share (TTM)
Dividend growth YoY
Dividend growth streak
Last ex-dividend
2025-04-29

Earnings calendar

2 metrics
Next earnings
Last earnings
2026-03-10

Profitability

9 metrics
Gross margin
Operating margin
Trailing 12 months
Net margin
Gross profit (TTM)
Operating profit (TTM)
−$164.74M
Net income (TTM)
−$153.24M
Trailing 12 months
Diluted EPS (TTM)
$8.44
FCF margin
Effective tax rate

Per share

11 metrics
Revenue per diluted share (TTM)
Gross profit per diluted share (TTM)
Operating profit per diluted share (TTM)
EBITDA per diluted share (TTM)
Net income per diluted share (TTM)
Operating cash flow per diluted share (TTM)
Free cash flow per diluted share (TTM)
Capital expenditures per diluted share (TTM)
R&D per diluted share (TTM)
Stock compensation per diluted share (TTM)
Book value per share
$-1,921.37

Growth

11 metrics
Revenue growth YoY
Year over year
Net income growth YoY
Revenue (TTM)
Trailing 12 months
EPS growth YoY
Shares change YoY
+114.7%
Year over year · more shares
Revenue CAGR (3Y)
Revenue CAGR (5Y)
EPS CAGR (3Y)
EPS CAGR (5Y)
FCF CAGR (3Y)
FCF CAGR (5Y)

Quality

14 metrics
Return on equity
-34.8%
Return on assets
-32.5%
Debt / equity
Current ratio
14.9
EBITDA (TTM)
Free cash flow (TTM)
Quick ratio
14.9
Interest coverage
Net debt / EBITDA
Return on invested capital
Trailing 12 months
Net cash
$461.20M
Latest balance sheet
Cash & equivalents
$107.25M
Total assets
$472.11M
Total debt

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$123.51M
Capital expenditures (TTM)
R&D (TTM)
$136.67M
SG&A (TTM)
Stock compensation (TTM)
$34.70M
R&D / revenue
Stock compensation / revenue

Ownership (13F)

3 metrics
13F filers
157
13F filer change QoQ
+35
Institutional ownership
114.8%

Short interest

3 metrics
Short interest
15.2%
Latest settlement · 10.2 days to cover
Days to cover
10.2d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
Insider-sentiment score

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1798749 CUSIP 008064206 13F (30d) 135 filings 134 filers Visit website Investor relations